By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > SNRI antidepressant > Duloxetine

Duloxetine

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|663 words

Duloxetine

What is Duloxetine?

Duloxetine is a prescription medication belonging to the class of antidepressants known as serotonin-norepinephrine reuptake inhibitors (SNRIs). It is commonly prescribed to treat major depressive disorder, generalized anxiety disorder, and certain chronic pain conditions. Unlike older antidepressants, duloxetine affects two key brain chemicals simultaneously, making it effective for both mood disorders and pain management.

Uses

Duloxetine has several FDA-approved therapeutic uses:

  • Major Depressive Disorder: Treatment of depression in adults, helping to improve mood, energy levels, and overall functioning
  • Generalized Anxiety Disorder: Management of excessive worry and anxiety symptoms that interfere with daily life
  • Diabetic Peripheral Neuropathy: Relief of nerve pain associated with diabetes, particularly in the hands and feet
  • Fibromyalgia: Treatment of chronic widespread muscle pain and tenderness characteristic of this condition
  • Chronic Musculoskeletal Pain: Management of ongoing pain conditions affecting muscles, bones, and joints

How it works

Duloxetine works by blocking the reuptake of two important neurotransmitters in the brain: serotonin and norepinephrine. By preventing these chemicals from being rapidly absorbed back into nerve cells, duloxetine increases their availability in the brain’s communication pathways. This dual action helps regulate mood and also affects pain perception pathways in the central nervous system, explaining why the medication is effective for both psychiatric and pain conditions.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Nausea and vomiting
  • Dry mouth
  • Drowsiness or fatigue
  • Constipation
  • Loss of appetite
  • Increased sweating
  • Dizziness
  • Sleep disturbances

Serious side effects that require immediate medical attention:

  • Suicidal thoughts or behaviors, especially in young adults
  • Severe liver problems (yellowing of skin or eyes, dark urine)
  • Serotonin syndrome (high fever, rapid heart rate, muscle rigidity)
  • Severe allergic reactions with difficulty breathing or swelling
  • Abnormal bleeding or bruising

Warnings and precautions

  • Suicide Risk: Duloxetine carries a black box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults under 25, particularly during the first few months of treatment
  • Liver Function: The medication is not recommended for patients with significant liver disease, as duloxetine is extensively metabolized by the liver and can potentially cause liver damage
  • Pregnancy and Breastfeeding: Duloxetine may pose risks during pregnancy, particularly in the third trimester, and can pass into breast milk, requiring careful consideration of benefits versus risks
  • Kidney Disease: Patients with severe kidney impairment should avoid duloxetine, as the medication and its metabolites are eliminated through the kidneys
  • Withdrawal Symptoms: Abrupt discontinuation can cause significant withdrawal symptoms, so the medication should be tapered gradually under medical supervision

Interactions

Duloxetine has several important drug interactions:

  • MAO Inhibitors: Can cause dangerous serotonin syndrome; require at least 14-day gap between medications
  • Blood Thinners (warfarin): Duloxetine may increase bleeding risk by affecting platelet function
  • NSAIDs and Aspirin: Combined use increases the risk of gastrointestinal bleeding
  • Other Serotonergic Drugs: SSRIs, triptans, and tramadol can increase serotonin syndrome risk
  • CYP1A2 Inhibitors: Medications like fluvoxamine can increase duloxetine levels in the blood
  • Thioridazine: Duloxetine can increase levels of this antipsychotic, potentially causing heart rhythm problems
  • St. John’s Wort: This herbal supplement can increase serotonin syndrome risk
  • Alcohol: Should be avoided as it increases the risk of liver damage and enhances sedation

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosing varies by condition being treated. For depression and anxiety, the usual starting dose is 30-60 mg once daily, which may be increased to a maximum of 120 mg daily based on response and tolerability. For diabetic neuropathy, the recommended dose is 60 mg once daily. For fibromyalgia, treatment typically begins at 30 mg daily for one week, then increases to 60 mg daily. Duloxetine should be taken with food to reduce nausea, and capsules should be swallowed whole without crushing or opening. All dosage adjustments should be made gradually and only under the guidance of a healthcare provider who can monitor for effectiveness and side effects.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Duloxetine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/duloxetine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Scientists Discover Master Clock That Controls Biological Growth and Development

Scientists have identified a genetic master clock that controls biological development timing.…

Brain immune cells reveal why some people resist dementia despite tau tangles

New Nature Medicine research reveals how brain immune cells determine whether people…

Climate Change Disrupts Education for 617 Million Children in Poverty Worldwide

Climate change is systematically disrupting education for 617 million children worldwide, with…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Desvenlafaxine

By
Prof. Giorgi Pkhakadze
02/06/2026

Milnacipran

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up